Contents

Contributors xiii

Interactions between Drugs and Nutrients
C. Tschanz, W. Wayne Stargel, and J. A. Thomas

I. Introduction 1
II. Factors Affecting Gastrointestinal Absorption 3
III. Bioavailability and Metabolism 8
IV. Excretion and Elimination 8
V. Special Interactions/Conditions 10
   A. Antimicrobials 10
   B. Drug–Ethanol Interactions 11
   C. Drug–Vitamins 14
   D. Drug–Minerals 15
   E. Genetic Differences 17
   F. Geriatrics 20
   G. Hypoglycemics 22
   H. Parenteral Nutrition 23
VI. Concluding Remarks 24
References 24

Induction of Cyclo-Oxygenase and Nitric Oxide Synthase in Inflammation
Ian Appleton, Annette Tomlinson, and Derek A. Willoughby

I. General Introduction 27
Current and Future Therapeutic Approaches to Hyperlipidemia

John A. Farmer and Antonio M. Gotto, Jr.

I. Introduction 79
In Vivo Pharmacological Effects of Ciclosporin and Some Analogues
Jean F. Borel, Götz Baumann, Ian Chapman, Peter Donatsch, Alfred Fahr, Edgar A. Mueller, and Jean-Marie Vigouret

I. Introduction and Summary 115
II. Molecular Mechanism of Immunosuppression 124
III. Suppressive Effects on Cell-Mediated Immunity 128
   A. T Cell-Mediated Cytotoxicity 128
   B. T-Cell Functions for Help, Memory, and Delayed-Type Hypersensitivity (DTH) 133
   C. Cell-Mediated Suppressor Function 137
   D. Induction of Antigen-Specific Hypo- or Unresponsiveness 143
IV. Other Biological Effects Associated with the Immunosuppressive Activity 154
   A. Chronic Inflammation 154
   B. Prolactin Antagonism 154
   C. Possible Interactions with the Central Nervous System 156
   D. Major Side Effects 158
V. Biological Effects Possibly Correlated with the Immunosuppressive Activity 165
   A. Development of Suppressor Cells 165
   B. Interference in the Regulation of Tolerance to Self and Nonself 165
   C. Therapeutic Effects in Psoriasis 172
   D. Therapeutic Effects in Asthma? 175
   E. Effects on Hair Follicles 179
VI. Biological Effects Appearing Independently of Immunosuppressive Activity 180
   A. Effects on Nonlymphoid Cells 180
   B. Effects on Various Cellular Functions 187
   C. Antibiotic Effects 189
VII. Chronic Allograft Rejection 194
   A. Clinical Situation 194
   B. Experimental Approaches 195
   C. Factors Involved in Chronic Allograft Rejection 199
VIII. Impact of Galenic Formulation on Pharmacokinetics 204
   A. Clinical Pharmacokinetics of CS (SANDIMMUN) 204
   B. New Galenical Formulation of CS (SANDIMMUN NEORAL) 207
References 208

Mono-ADP-ribosylation: A Reversible Posttranslational Modification of Proteins
Ian J. Okazaki and Joel Moss

I. Introduction 247
II. Mono-ADP-ribosyltransferases 250
   A. Avian ADP-ribosyltransferases 250
   B. Mammalian ADP-ribosyltransferases 256
   C. Inhibitors of Mono-ADP-ribosyltransferase 261
III. Conserved Regions among ADP-ribosyltransferases 262
   A. Region I 263
   B. Region II 265
   C. Region III 266
IV. ADP-ribosylarginine Hydrolases 268
   A. Turkey ADP-ribosylarginine Hydrolase 269
   B. Mammalian ADP-ribosylarginine Hydrolases 270
V. Summary 271
References 272

Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer
Samuel R. Denmeade and John T. Isaacs

I. Overview of the Problem 281
II. Androgen Sensitivity of Prostate Cancer 282
Reversal of Atherosclerosis with Therapy: Update of Coronary Angiographic Trials

Howard N. Hodis

I. Overview 307

II. Coronary Angiographic Trials Utilizing Pharmacological Intervention 308
   A. The NHLBI Type II Coronary Intervention Study 308
   B. The Cholesterol-Lowering Atherosclerosis Study (CLAS) 308
   C. The Familial Atherosclerosis Treatment Study (FATS) 309
   D. The University of California, San Francisco, Specialized Center of Research Intervention Trial (UCSF SCOR) 309
   E. The Monitored Atherosclerosis Regression Study (MARS) 310
   F. The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) 311
   G. Multicentre Anti-Atheroma Study (MAAS) 314
   H. The Stanford Coronary Risk Intervention Project (SCRIP) 314
   I. The St. Thomas’ Atherosclerosis Regression Study (STARS) 315
Contents

III. Coronary Angiographic Trials Utilizing Nonpharmacological Intervention 315
   A. The Leiden Intervention Trial 315
   B. The Lifestyle Heart Trial 316
   C. Heidelberg Exercise–Diet Study 316
   D. The Program on the Surgical Control of the Hyperlipidemias (POSCH) 317

IV. Summary of the Coronary Angiographic Trials 317
V. Conclusions from Coronary Angiographic Trials 317
References 318

Unnatural Nucleotide Sequences in Biopharmaceutics
Lawrence A. Loeb

I. Introduction 321
II. Site-Specific Mutagenesis and Rational Drug Design 322
III. Molecular Evolution and Its Consequences 323
IV. Random Molecular and Chemical Libraries 324
   A. Random Genetic Selection for Biologically Active Proteins 324
   B. Phage Display Libraries for Binding Proteins 324
   C. Peptide Libraries for Modeling Peptide Hormones and Drugs 326
   D. Nucleic Acid Libraries 326
   E. Combinatorial Chemical Libraries 328
V. Random Sequence Selection 328
   A. General Protocol 328
   B. Choice of a Plasmid Vector and Host 329
   C. “Dummy” or Nonfunctional Inserts 330
   D. Oligonucleotide Inserts Containing Random Nucleotide Sequences 330
   E. Randomization of Oligonucleotides 331
   F. Combinatorial Consideration 332
VI. Applications of Random Sequence Selection 333
VII. Regulatory DNA Sequences and Binding Proteins 333
VIII. Production of Mutant Enzymes 334
    A. β-Lactamase 334
    B. Related Studies 335
IX. Gene Therapy for Human Cancer 336
    A. Herpes Thymidine Kinase 336
    B. Protection of Bone Marrow 341
X. Status, Summary, and Future Prospects 343
References 344
Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996), and Insights into Its Mechanism of Action
Simon P. Aiken, Robert Zaczek, and Barry S. Brown

I. Introduction 349
   A. The Unmet Medical Need of Alzheimer's Disease 349
   B. The Cholinergic Hypothesis of Alzheimer's Disease 350
   C. Rationale behind the Use of Linopirdine 351

II. Pharmacology of Linopirdine 353
   A. Enhancement of Evoked Neurotransmitter Release by Linopirdine 353
   B. Behavioral Effects of Linopirdine 358
   C. Other Effects of Linopirdine 361

III. Mechanistic Studies on Linopirdine 364
   A. Neurochemical Studies 364
   B. Electrophysiological Studies 371

References 380

Index 385
Contents of Previous Volumes 395